SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
6 references·0 citing·28 second hop
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis (2019)Lenvatinib Versus Sorafenib as First-Line…Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan (2019)Cost-effectiveness analysis o…Assessment of costs associated with adverse events in patients with cancer (2018)Assessment of costs associate…Health care costs associated with hepatocellular carcinoma: A population-based study (2013)Health care costs associated …Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer (2013)Cost-Effectiveness of Systemi…Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Enhanced secondary analysis o…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010)Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data (2013)Choosing effect measures and computing estimates of effect (2019)IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves (2021)Cost-Effectiveness in Health and Medicine (1996)Quality of life and pharmacoeconomics in clinical trials (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Interpretation of cost-effectiveness analyses (1998)Making choices in health: who guide to cost-effectiveness analysis (2004)Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021)Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care (1995)Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data (2002)Cost of Care for Elderly Cancer Patients in the United States (2008)Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States (2017)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force (2013)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer (2018)First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis (2019)Methods for the economic evaluation of health care programmes (1987)Methods for the Economic Evaluation of Health Care Programmes (2005)Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 (2012)Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (2021)
this work references cited by second hop

References

  • 2012Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves2,553 cited
  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2018Assessment of costs associated with adverse events in patients with cancer168 cited
  • 2013Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer87 cited
  • 2019Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan82 cited
  • 2013Health care costs associated with hepatocellular carcinoma: A population-based study79 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work